Sickle cell disease in Ontario, Canada: an epidemiologic profile based on health administrative data

Background: The number of patients with sickle cell disease in Ontario, Canada, is unknown. In the absence of a formal registry, we performed a study to determine an approximate census via analysis of health administrative databases. Methods: We identified Ontario patients with a diagnosis of sickle cell disease through queries of the Discharge Abstract Database, National Ambulatory Care Reporting System and Newborn Screening Ontario database. The period of inquiry was Apr. 1, 2007, through Mar. 31, 2017. We identified repeat interactions by the same patient by cross-referencing provincial health insurance plan numbers. Results: We documented health care system interactions for 3418 unique patients (1912 [55.9%] female, median age at the time of identification 24 yr). Over the 10-year study period, patients visited the emergency department a median of 2 (interquartile range [IQR] 1–7) times and an average of 6.69 (standard deviation [SD] 26.71) times, and were admitted to hospital a median of 1 (IQR 1–5) time and an average of 4.38 (SD 8.53) times for treatment related to sickle cell disease. A total of 229 patients (6.7%) died during the study period, with an average age at death of 55 years. Even without accounting for the effects of immigration, the rate of natural increase slowed slightly over the study period owing to a decrease in the annual number of affected births. Interpretation: The estimated prevalence of patients with sickle cell disease in Ontario in 2007/08–2016/17 was 1 in 4200, and affected patients’ need for hospital-based care was substantial, although highly variable. Similar queries of health administrative databases may be feasible in other Canadian provinces.

[1]  Vijay Kumar Chattu,et al.  Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021 , 2023, The Lancet. Haematology.

[2]  J. Parboosingh,et al.  The Alberta Newborn Screening Approach for Sickle Cell Disease: The Advantages of Molecular Testing , 2021, International journal of neonatal screening.

[3]  M. Castonguay,et al.  COVID-19 and Sickle Cell Disease in the Province of Quebec: Morbidity and Mortality Rates Derived from the Provincial Registry , 2021, Blood.

[4]  S. Grosse,et al.  Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research , 2020, Pediatric blood & cancer.

[5]  M. DeBaun,et al.  Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low‐resource setting: evidence from the SPRING trial , 2020, British journal of haematology.

[6]  E. Akl,et al.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. , 2020, Blood advances.

[7]  A. Kulozik,et al.  Sickle cell disease in Germany: Results from a national registry , 2019, Pediatric blood & cancer.

[8]  P. Chakraborty,et al.  Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013 , 2018, Blood.

[9]  Á. Cervera,et al.  National registry of hemoglobinopathies in Spain (REPHem) , 2017, Pediatric blood & cancer.

[10]  M. Hulihan,et al.  Emergency department utilization by Californians with sickle cell disease, 2005–2014 , 2017, Pediatric blood & cancer.

[11]  K. Wailoo Sickle Cell Disease - A History of Progress and Peril. , 2017, The New England journal of medicine.

[12]  A. Qureshi,et al.  Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion , 2017, British journal of haematology.

[13]  C. Steiner,et al.  Trends in Hospitalizations With a Red Blood Cell Transfusion, 2000–2013 , 2016 .

[14]  A. Douiri,et al.  Survival in adults with sickle cell disease in a high-income setting. , 2016, Blood.

[15]  V. Gordeuk,et al.  Blood transfusion and 30‐day readmission rate in adult patients hospitalized with sickle cell disease crisis , 2015, Transfusion.

[16]  Xueqing Yu,et al.  Sex difference of autosomal alleles in populations of European and African descent , 2015, Genes & Genomics.

[17]  Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 , 2014, Pediatrics.

[18]  A. Tatem,et al.  Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000 , 2014, The Lancet. Global health.

[19]  J. Gurney,et al.  Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program , 2013, PloS one.

[20]  M. Gladwin,et al.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. , 2011, JAMA.

[21]  Pamela L Owens,et al.  Acute care utilization and rehospitalizations for sickle cell disease. , 2010, JAMA.

[22]  P. Kavanagh,et al.  Sickle cell disease-related pediatric medical expenditures in the U.S. , 2010, American journal of preventive medicine.

[23]  K. Hassell Population estimates of sickle cell disease in the U.S. , 2010, American journal of preventive medicine.

[24]  S. Ballas The cost of health care for patients with sickle cell disease , 2009, American journal of hematology.

[25]  A. Hartzema,et al.  The cost of health care for children and adults with sickle cell disease , 2009, American journal of hematology.

[26]  A. Giardino,et al.  Healthcare utilization and expenditures for low income children with sickle cell disease , 2009, Pediatric blood & cancer.

[27]  Cage S. Johnson,et al.  Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.

[28]  P. Lane Sickle cell disease. , 1996, Pediatric clinics of North America.

[29]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[30]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[31]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[32]  K. Baum,et al.  The Painful Crisis of Homozygous Sickle Cell Disease: A Study of Risk Factors , 1987 .

[33]  Michel Tousignant,et al.  Children’s understanding of the relationship between addition and subtraction , 2008, Cognition.